Carol Lippa MD

Movement Disorder, Neurodegenerative, Dementia & Geriatrics

Director, Cognitive Disorders and Comprehensive Alzheimer's Disease Center at Thomas Jefferson University. Director, Division of Cognitive Disorders, Department of Neurology.

Join to View Full Profile

909 Walnut StPhiladelphia, PA 19107
Phone+1 215-955-1234
Fax+1 215-923-6792

Summary

Board certified neurologist with an international reputation in academic neurology, who has directed cognitive disorders programs for over 20 years. Currently bringing together experts from various disciplines to develop a Cognitive and Comprehensive Alzheimer’s disease clinical, research and education Center within the Farber Institute for Neuroscience and TJU department of Neurology to provide patients and families more accurate and earlier diagnosis and intervention, expand and solidify the related translational research units and develop education/training initiatives.

Clinical Expertise

Alzheimer's disease, Alzheimer Vaccines, Vascular dementia, Lewy body dementia, Parkinson's disease, Frontotemporal lobar degeneration , Cognitive disorders, Concussion, Clinical research, Clincial trials, Behavioral neurology / Neuropsychiatry, General neurology, Geriatrics / Dementia, Movement disorders, Depressed skull fractures, Post-partum depression, Sexual aversion disorder, Diabetes

Education & Training

University of Massachusetts Medical SchoolFellowship, Neuropathology, 1987 - 1988
UMass Chan Medical SchoolResidency, Neurology, 1983 - 1987
University of Massachusetts Medical SchoolClass of 1983

Certifications & Licensure

PA State Medical License 1995 - 2026
NJ State Medical License 2018 - 2025
MA State Medical License 1988 - 2005
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia Start of enrollment: 2006 Nov 01
Completed
Phase 4
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies.
David G Coughlin, Karen R MacLeod, John S Middleton, Andrea C Bozoki, James E Galvin
Neurology. 2024-08-13
2 citations
Metabolic and Environmental Biomarkers in Mild Cognitive Impairment and Dementia: An Exploratory Study.
Abigail C Lyon, Carol F Lippa, Arnold R Eiser
Journal of Integrative and Complementary Medicine. 2024-08-01
5 citations
ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.
Lavanya Jain, Maria Khrestian, Shane Formica, Elizabeth D Tuason, Jagan A Pillai
Alzheimer's & Dementia. 2024-01-01

Press Mentions

Health: Cocoa & the Brain, Restoring Your Younger MindMay 6th, 2016

Grant Support

International Multispecialty Conference On PDD And DLBNational Institute Of Neurological Disorders And Stroke2006
Dementia With Parkinsonism: What Are We Diagnosing?National Institute On Aging1998–1999
Dementia With Parkinsonism: What Are We Diagnosing?National Institute On Aging1998
UnknownNational Institute On Aging1996–1997
Dementia With Parkinsonism--What Are We Diagnosing?National Institute On Aging1995